Surufatinib not checked
HUTCHMED · HMPL-012 · HMPL-012 plus JS001
FollowEvery change as it happens, and a Monday email
Trials
1 active
14 in total
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8”In the company’s words, NCT06361888 on ClinicalTrials.gov
- Tested for
- Metastatic Pancreatic Cancer
- Main trialPhase 2/3
- “To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer”In the company’s words, NCT06361888 on ClinicalTrials.gov
- Other names
- HMPL-012 · Sulfatinb · sulfatinib · HMPL-012 plus JS001
Other drugs for Metastatic Pancreatic Cancer
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up1
- 31 May 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 May 2028 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | |
| Phase 3Completed | 31 Mar 2019 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | |
| Phase 3Completed | 11 Nov 2019 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | |
| Phase 3Unknown | 31 May 2025 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | |
| Phase 2Completed | 28 Feb 2023 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | |
| Phase 2Completed | 31 Jul 2024 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | |
| Phase 2Terminated | 6 Sep 2024 | Open-Label Surufatinib in European Patients With NET | |
| Phase 1/2Completed | 25 Apr 2023 | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | |
| Phase 1/2Completed | 25 Apr 2023 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | |
| Phase 1/2Completed | 6 Sep 2024 | Open-label Study of Surufatinib in Japanese Patients | |
| Phase 1Completed | 29 Sep 2020 | A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | |
| Phase 1Completed | 31 Oct 2020 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | |
| Phase 1Completed | 21 Aug 2021 | Surufatinib Renal Impairment Study | |
| Phase 1Completed | 11 Oct 2021 | Surufatinib Hepatic Impairment Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026